b3c newswire

Vectron Biosolutions Obtains Strong Results for Biosimilar Production
(Fri, 10 Feb 2012 09:45:00 +0000)  B3C newswire (http://www.b3cnewswire.com/home.html) - Vectron Biosolutions (http://www.vectronbiosolutions.com/) announced today that they have obtained strong results for manufacture of selected biosimilar proteins using their proprietary E. coli expression technology. The study was done side-by-side with other expression technologies and Vectron’s technology gave higher soluble and/or insoluble yields for seven out of 10 tested biosimilar proteins. The increase in yield was 2 to 25 times compared to the best conventional technology. The biosimilar proteins that were produced more efficiently with Vectron’s technology

Sistemic to Work with TiGenix On Landmark EUR 5. ...
(Tue, 07 Feb 2012 15:15:00 +0000)  B3C newswire (http://www.b3cnewswire.com/home.html) Sistemic (http://www.sistemic.co.uk) is delighted to announce that its proprietary technology (SistemQC™ (http://www.sistemic.co.uk/cell-therapy/)) has been chosen to form a key part of the research and production process for a landmark multinational collaborative project led by TiGenix, Belgium and including partners from Spain, France, the Netherlands as well as the UK and Belgium. The project, REGENER-AR, will bring the first stem cell therapy treatment product for rheumatoid arthritis, Cx611, through final research and clinical development. The proprietary SistemQC™

Xceleron Announces New Investment and Move to Purpose-Built Laboratories in U.S.
(Mon, 06 Feb 2012 09:00:00 +0000)  B3C newswire (http://www.b3cnewswire.com/home.html) / – Xceleron (http://www.xceleron.com/), a leader in accelerating drug development using ultra-sensitive bioanalytical analyses, today announced that existing investors Albion Ventures and Solon Ventures have invested $2.4MM to locate all of the company’s business in its custom-built facility in Germantown, MD which is expected to be fully operational by 31st March 2012. Xceleron is relocating senior analytical staff to Germantown from York, hiring new staff in Maryland and retaining

IDEA Bio-Medical Sells HTS/HCS Cell Imaging System to The Medical University of South Carolina
(Thu, 02 Feb 2012 14:00:00 +0000)  B3C newswire (http://www.b3cnewswire.com/home.html) - IDEA Bio-Medical Ltd. (http://www.idea-bio.com) and The Medical University of South Carolina (MUSC) announced today that they have completed the sale of IDEA Bio-Medical’s breakthrough Hermes WiScan® system (http://www.idea-bio.com/?_url=products) to MUSC’s Center for Drug Discovery. Hermes WiScan® is a breakthrough biological cell imaging desktop system that enables researchers, at all levels, to run a wide variety of biological applications at the push-of-a-button, using an extremely easy-to-use (tablet-style) touchscreen mechanism. “Our goal was to develop

Biotage Introduces Biotage® SNAP Ultra High Performance Flash Chromatography Cartridges
(Tue, 31 Jan 2012 16:30:00 +0000)  B3C newswire (http://www.b3cnewswire.com/home.html) / – Biotage (http://www.biotage.com) (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, introduced the new Biotage® SNAP Ultra high performance flash chromatography cartridges utilizing Biotage® HP-Sphere™ spherical silica. Biotage® SNAP Ultra is available in a wide range of sizes from 10 g – 340 g. Biotage® HP-Sphere™ is chromatographically tested proprietary silica with 40% more surface area than previously available flash silica in the same high performance category, improving loading capacity and

Definiens Strengthens Leadership with Key Appointment
(Tue, 31 Jan 2012 16:00:00 +0000)   Former Aperio Executive and Digital Pathology Market Expert, Dr. Martin Stuart, Joins Executive Team Munich, Germany, January 31, 2012 B3C newswire (http://www.b3cnewswire.com/home.html) - Definiens (http://www.definiens.com/), the global leader in Health Image Intelligence and Quantitative Digital Pathology, has appointed Martin Stuart (http://www.definiens.com/about-definiens/our-company/management-team.html), PhD, as its Executive Vice President and General Manager North America and Asian Pacific. In his new role, Stuart will be responsible for expanding the Definiens business in North America and Asia and providing leadership to the sales and field operations. Martin Stuart, a former Senior Vice President

Roche Diagnostics Announces Dan Zabrowski as New Head of Roche Applied Science
(Tue, 31 Jan 2012 13:00:00 +0000)   Penzberg, Germany, January 31, 2012 B3C newswire (http://www.b3cnewswire.com/home.html) - As of February 1, 2012, Dan Zabrowski is Head of Roche Applied Science in the Diagnostics Division, located in Penzberg, Germany. He succeeds Paul Brown who has led Roche Applied Science since September 2011. Dan Zabrowski will report to Daniel O’Day, COO Roche Diagnostics. Dan recently served as Global Head of Roche Partnering and was a member of the Roche Corporate Executive Committee and Chugai Board. He joined Roche in 1994 through the acquisition of Syntex. During his career at Roche, Dan

Rentschler Announces 2. Laupheimer Zelltage on Industrial Cell Culture Technology
(Mon, 30 Jan 2012 13:00:00 +0000)  B3C newswire (http://www.b3cnewswire.com/home.html) - Rentschler Biotechnologie GmbH (http://www.rentschler.de/index.php?L=1) is pleased to announce the second Laupheimer Zelltage, a biennial industrial cell culture technology conference to be held on June 11-12, 2012 at Laupheim's historical castle, Schloss Großlaupheim. The aim of the Laupheimer Zelltage conferences is to provide comprehensive scientific updates on cutting-edge technologies and to discuss application-oriented topics as a means to advance protein and virus-based biologics production. The conference will bring together 200 academic and industrial experts on cell

AMSilk to Be Featured on 21st Century Business Television on CNBC and Fox Business Network
(Thu, 26 Jan 2012 10:00:00 +0000)  B3C newswire (http://www.b3cnewswire.com/home.html) - AMSilk (http://www.amsilk.com/en.html) is pleased to announce that the company will be featured in the 21st Century Business series on Fox Business Network this week, Saturday the 28th of January at 4:30 pm ET (3:30 CT, 2:30 MT, 1:30 PT) .The week’s segment on AMSilk’s Innovative High Performance Spider Silk Materials. AMSilk CEO, Axel Leimer explains the company’s award winning technology, copying one of nature’s most coveted high-performance materials, spider silk, with a commercial production process, to studio host Jackie

Rentschler Manufacturing Facility Wins 2012 Facility of the Year Award in Equipment Innovation
(Wed, 25 Jan 2012 15:00:00 +0000)   B3C newswire (http://www.b3cnewswire.com/home.html) / - Rentschler Biotechnologie GmbH (http://www.rentschler.de/?L=1), a full-service contract biomanufacturing company, is pleased to announce that the company’s new manufacturing facility has won the 2012 Facility of the Year Award (http://www.facilityoftheyear.org/) (FOYA) in the category Equipment Innovation. The award recognizes Rentschler for its flexible, multi-product manufacturing facility designed to minimize manufacturing costs and product cycle times. The Facility of the Year Award

Encap Drug Delivery Adds New Commercial Product to Portfolio
(Wed, 25 Jan 2012 12:15:00 +0000)  B3C newswire (http://www.b3cnewswire.com/home.html) Encap Drug Delivery (http://www.encapdrugdelivery.com), the world’s leading contract development and manufacturing organization (CDMO) totally dedicated to liquid and semi-solid (hot melt) filled capsules, announces the addition of a further pharmaceutical product to its portfolio of commercial products. The privately held company, founded 23 years ago, has spent the last few years building its development services capability and has state of the art manufacturing facilities based in Livingston (United Kingdom). The company has been successfully audited by

Affectis Granted Patent for AFC-5128, other P2X7 Antagonists
(Wed, 25 Jan 2012 10:30:00 +0000)  B3C newswire (http://www.b3cnewswire.com/home.html) – Affectis Pharmaceuticals AG (http://www.affectis.com/), a pharmaceutical company developing novel drugs for the treatment of neuroinflammatory diseases, announced today that the European Patent Office has granted a key patent for its oral brain-penetrant P2X7 antagonist AFC-5128 which is being developed for the treatment of neuropathic pain and multiple sclerosis. The European patent EP2105164 is related to the composition of AFC-5128, a highly potent orally active P2X7 antagonist. A key advantage of the compound is its ability to cross the

Boehringer Ingelheim Prolongates Drug Discovery Collaboration with Priaxon
(Tue, 24 Jan 2012 14:30:00 +0000)  B3C newswire (http://www.b3cnewswire.com/home.html) / – Priaxon (http://www.priaxon.com), utilizing its proprietory PriaXplore® platform for small molecule drug discovery, and Boehringer Ingelheim will prolongate their research and development collaboration on mdm2/p53 inhibitors for the treatment of cancer.The companies will continue working jointly to identify and advance drug candidates into pre-clinical development. Thereafter, Boehringer Ingelheim will drive the development and commercialisation of the potential cancer treatments arising from the collaboration. " Priaxon has been able to develop promising mdm2/p53 inhibitors with its PriaXplore®

Sartorius Stedim Biotech and Refine Technology Announce Cooperation
(Mon, 23 Jan 2012 16:15:00 +0000)   B3C newswire (http://www.b3cnewswire.com/home.html) / – Sartorius Stedim Biotech (http://www.sartorius-stedim.com) (SSB), a leading international pharma supplier, and Refine Technology (http://www.refinetech.com) (Refine), the developer and worldwide supplier to the biotech industry of the ATF™ System, a best-in-class cell retention device, will be collaborating on the development of a robust platform for high-density

Biotage Releases New Catalog and Technical Guide for Sample Preparation and Evaporation
(Wed, 18 Jan 2012 16:30:00 +0000)  B3C newswire (http://www.b3cnewswire.com/home.html) – www.biotage.com (http://www.biotage.com). New additions include the updated Biotage® RapidTrace®+ automated SPE workstation with enhanced features

Hinweis: Der Feed "b3c newswire" und dessen hier dargestellten RSS-Inhalte liegen urheberrechtlich beim Autor der Betreiber-URL (siehe RSS-Link). Auf den Inhalt von "b3c newswire" hat RSS-Nachrichten.de keinen Einfluss. (31611-7-129-1 - 0)